Clinical Trial

A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old

Study acronym: SUGAPEDIA
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Sugammadex is a drug used more and more frequently in infants as a rocuronium' s reversal agent. It has multiples benefits over other reversal agents such as a rapid onset of action and a complete reversal no matter how deep is the neuromuscular blockade. The dosage of sugammadex used in current clinical practice is the same as in adults based on empirical evidence. Futhermore some multricentric studies showed that that dosage might not be appropriate for infants younger than 2 years old. The goal of this study is to determine the correct dosage of sugammadex to use in infants younger than 2 years old.
Trial Details
NCT Number NCT07477132
Lead Sponsor University Hospital, Caen
Conditions Curarization, Postoperative Residual
Enrollment 99 participants
Start Date 2026-03-30
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-17